Home
About
About I-MAK
Our Work
I-Mak Directors
Board Of Directors
Advisory Board
Partners
Contact
Our Cases
Our Cases
FAQs
Lopinavir/Ritonavir
Abacavir Sulfate
Nevirapine Hemihydrate
Oseltamivir
Tenofovir
Testimonials
Media Center
Video/Audio
News Releases
Media Articles
Bios & Photos
Resources
I-MAK Blog
Archive
Publications
Presentations
Patent Landscapes
Pharmaceutical Patent Decisions
Patent Information & Databases
IP & Health Links
Donate
I-MAK
Initiative For Medicines, Access & Knowledge
Home
About
About I-MAK
Our Work
I-Mak Directors
Board Of Directors
Advisory Board
Partners
Contact
Our Cases
Our Cases
FAQs
Lopinavir/Ritonavir
Abacavir Sulfate
Nevirapine Hemihydrate
Oseltamivir
Tenofovir
Testimonials
Media Center
Video/Audio
News Releases
Media Articles
Bios & Photos
Resources
I-MAK Blog
Archive
Publications
Presentations
Patent Landscapes
Pharmaceutical Patent Decisions
Patent Information & Databases
IP & Health Links
Donate
Home
About
About I-MAK
Our Work
I-Mak Directors
Board Of Directors
Advisory Board
Partners
Contact
Our Cases
Our Cases
FAQs
Lopinavir/Ritonavir
Abacavir Sulfate
Nevirapine Hemihydrate
Oseltamivir
Tenofovir
Testimonials
Media Center
Video/Audio
News Releases
Media Articles
Bios & Photos
Resources
I-MAK Blog
Archive
Publications
Presentations
Patent Landscapes
Pharmaceutical Patent Decisions
Patent Information & Databases
IP & Health Links
Donate
Search
Subscribe Via RSS
Or Email
Enter your email address:
Delivered by
FeedBurner
Main
|
Priti Radhakrishnan Speaks About the Future of Trade and Access to Medcinines at the Spotlight on the Millennials »
Thursday
Mar
03
2011
Tahir Amin Speaks to NDTV About the Recent Victory Against Abbott Laboratories HIV Drug Patent
Thursday, March 3, 2011 at 12:39PM
I-Mak
|
Post a Comment
|
Share Article
Reader Comments
There are no comments for this journal entry. To create a new comment, use the form below.
Post a New Comment
Enter your information below to add a new comment.
My response is on my own website »
Author:
(forget stored information)
Author Email (optional):
Author URL (optional):
Post:
↓
|
↑
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
Link an External Response
Have a response on your own site? You can either use the [
Trackback URL
] for this entry, or link to your response directly.
I want to leave a comment directly on this site »
Article Title:
Article URL:
Article Excerpt (optional):
Site Name:
Site URL (optional):
Author Name:
Except for publications commissioned or published by third parties all content on this site is licensed under a
Creative Commons Attribution 3.0 License
Reader Comments